# Pyxis Oncology to Participate in Upcoming Investor Conferences
Canonical URL: https://biopharmsignal.com/news/PYXS/pyxis-oncology-to-participate-in-upcoming-investor-conferences-c593dd86
Ticker: PYXS
Company: Pyxis Oncology
Source: Pyxis Oncology
Published: 2026-05-13 11:30 EST
## Summary

Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for...

## Article Body
Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management will participate in the following upcoming investor conferences:

RBC Capital Markets Global Healthcare Conference in New York, NY on Tuesday, May 19, 2026, fireside chat at 2:35 p.m. ET; and

Stifel Virtual Oncology Forum on Wednesday, May 20, 2026, fireside chat at 3:30 p.m. ET; and

Jefferies Global Healthcare Conference in New York, NY on Thursday, June 4, 2026, fireside chat at 7:35 a.m. ET.

Live webcasts and replays of the fireside chats will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, ir.pyxisoncology.com .

About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers. The Company’s lead candidate, micvotabart pelidotin (MICVO), is a first-in-concept antibody drug conjugate (ADC) that targets extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix (ECM). EDB+FN is selectively overexpressed in the tumor microenvironment of a wide range of solid tumors and largely absent from normal adult tissues. MICVO is designed to treat solid tumors through a three-pronged mechanism of action: direct cancer cell killing, bystander effect and immunogenic cell death. MICVO is currently being evaluated as monotherapy in a Phase 1 clinical study in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in a Phase 1/2 clinical study in patients with R/M HNSCC and other solid tumors. Pyxis Oncology is focused on advancing MICVO, with the goal of improving outcomes for patients living with R/M HNSCC and contributing to meaningful progress in cancer treatment.

MICVO received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of adult patients with R/M HNSCC whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 therapy.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

To learn more, visit www.pyxisoncology.com or follow us on LinkedIn .

Pyxis Oncology Contact Alex Kane IR@pyxisoncology.com
## Recent Company News
- 2026-06-30 11:30 EST — [Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones](https://biopharmsignal.com/news/PYXS/pyxis-oncology-announces-up-to-114-million-private-placement-financing-to-advanc-a7414ffd) — Source: Pyxis Oncology
- 2026-05-14 11:00 EST — [Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones](https://biopharmsignal.com/news/PYXS/pyxis-oncology-reports-first-quarter-2026-financial-results-and-advances-micvo-t-3b0d67d9) — Source: Pyxis Oncology
- 2026-05-13 11:30 EST — [Pyxis Oncology to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/PYXS/pyxis-oncology-to-participate-in-upcoming-investor-conferences-c593dd86) — Source: Pyxis Oncology
- 2026-05-07 20:05 EST — [Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer](https://biopharmsignal.com/news/PYXS/pyxis-oncology-appoints-nelson-azoulay-as-chief-business-officer-ac9a049b) — Source: Pyxis Oncology
- 2026-04-17 20:05 EST — [Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026](https://biopharmsignal.com/news/PYXS/pyxis-oncology-to-present-new-preclinical-data-showing-synergistic-anti-tumor-ac-5b636925) — Source: Pyxis Oncology
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)